Pharmena S.A.

Warsaw Stock Exchange PHR.WA

Pharmena S.A. Net Cash Used Provided By Financing Activities for the year ending December 31, 2023: USD -2.35 M

Pharmena S.A. Net Cash Used Provided By Financing Activities is USD -2.35 M for the year ending December 31, 2023, a -601.88% change year over year. Net cash used/provided by financing activities are the total cash inflows and outflows related to activities that finance the company’s operations, including debt, equity, and dividends.
  • Pharmena S.A. Net Cash Used Provided By Financing Activities for the year ending December 31, 2022 was USD -334.60 K, a -142.08% change year over year.
  • Pharmena S.A. Net Cash Used Provided By Financing Activities for the year ending December 31, 2021 was USD 795.08 K, a -4.66% change year over year.
  • Pharmena S.A. Net Cash Used Provided By Financing Activities for the year ending December 31, 2020 was USD 833.98 K, a -77.36% change year over year.
  • Pharmena S.A. Net Cash Used Provided By Financing Activities for the year ending December 31, 2019 was USD 3.68 M, a 572.70% change year over year.
Key data
Date Net Cash Used Provided By Financing Activities Dividends Paid Capital Expenditure Effect Of Forex Changes On Cash
Market news
Loading...
SV Wall Street
Warsaw Stock Exchange: PHR.WA

Pharmena S.A.

CEO Mr. Konrad Palka
IPO Date Aug. 1, 2008
Location Poland
Headquarters ul. Wólczanska 178
Employees 15
Sector Consumers Staples
Industries
Description

Pharmena S.A., a biotechnology company, manufactures and sells active ingredients in various areas of medicines in Poland and internationally. The company offers dermatological cosmetics, including skin, hair, and nail care products, as well as dietary supplement for atherosclerosis prophylaxis. It offers its products under the Menavitin, Dermena, Allerco, and Thermi names. The company is developing 1-MNA, an anti-atherosclerosis drug which is under phase II clinical trial. Pharmena S.A. was founded in 2002 and is based in Lódz, Poland. Pharmena S.A. is a subsidiary of Pelion S.A.

StockViz Staff

February 6, 2025

Any question? Send us an email